KUOW - This Ivy League wages hand-to-leaf combat against an English strangler kuow.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuow.org Daily Mail and Mail on Sunday newspapers.
Credit Suisse Group AG has agreed to pay nearly $475 million to U.S. and U.K authorities, including nearly $100 million to the Securities and Exchange Commission, for fraudulently misleading investors and violating the Foreign Corrupt Practices Act (FCPA) in a scheme involving two bond offerings and a syndicated loan that raised funds on behalf of state-owned entities in Mozambique.
SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device
Washington, D.C. (Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading stat
FOR IMMEDIATE RELEASE Washington D.C., Dec. 18, 2020
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics Covid-19 device an